Epstein Secrets

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees - 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACART CAPITAL LLC EFTA_R1_01138845 EFTA02295571 Return on Investment X

er and Senior Vice President of medical affairs at Cell Genesys. He oversaw all clinical, regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also prev

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98

er and Senior Vice President of medical affairs at Cell Genesys. He oversaw all clinical, regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also prev

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. S

er and Senior Vice President of medical affairs at Cell Genesys. He oversaw all clinical, regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also prev